Coya Therapeutics has expanded and strengthened its patent estate beyond COYA 302, which is a combination of COYA 301 with CTLA-4 Ig. This license with UNeMed Corporation or UNeMed , the Technology Transfer Office of University of Nebraska Medical Center, covers the combination of COYA 301 with GM-CSF and additional immune analogues and provides a next generation approach with a novel combination to synergistically modulate and reduce inflammation. UNeMed will receive payments upon achievement of certain milestones and will be eligible to receive tiered low single-digit royalty on net sales. “We believe that COYA 301 is ideally situated to serve as a backbone drug in combination with other biologics that synergistically modulate the immune system and represent next generation approaches to treating inflammatory disorders, which are driven by complex and multi-factorial pathways. Enhancing Treg activity with COYA 301 in combination with GM-CSF and additional immune analogues creates yet another novel biologic combination in addition to Coya’s lead asset, COYA 302 and expands optionality and potential partnerships,” stated Arun Swaminathan Ph.D., Chief Business Officer. ..Michael Dixon, Ph.D., President and CEO of UNeMed, noted, “This agreement with Coya can potentially bring new therapies to patients suffering from neurodegenerative conditions. Coya’s foundation and progress in low-dose IL-2 research makes them an ideal company to leverage our findings to date.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on COYA:
- Coya Therapeutics to host conference call
- Coya Therapeutics Boosts Finances with Dr. Reddy’s Deal
- Coya expands pipeline for COYA 302 beyond ALS to include FTD and PD
- Coya announces pre-IND meeting, Type C meeting with FDA for COYA 302
- Coya Therapeutics files to sell 4.69M shares of common stock for holders